Ultragenyx Pharmaceutical Profit Margin 2012-2021 | RARE
Current and historical gross margin, operating margin and net profit margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Ultragenyx Pharmaceutical net profit margin as of June 30, 2021 is -97.79%.
|Ultragenyx Pharmaceutical Annual Profit Margins
|Ultragenyx Pharmaceutical Quarterly Profit Margins
||Medical - Biomedical and Genetics
Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.